The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study
Background: There is currently a lack of sufficient evidence on the prognosis of human epidermal factor receptor 2 (HER2)-positive microinvasive breast cancer (MIBC) and whether chemotherapy (CT) and targeted therapy can bring benefits. Objectives: To explore the prognosis and treatment of HER2-posi...
Saved in:
| Main Authors: | Bo Lan, Dan Lv, Changyuan Guo, Zitong Feng, Ying Fan, Tao Sun, Jiayi Huang, Xiaoying Sun, Fei Ma, Binghe Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251345716 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical characteristics and predictive models of HER2-low breast cancer patients who only received adjuvant chemotherapy: a real-world retrospective multicenter study
by: Qinchuan Wang, et al.
Published: (2025-07-01) -
Microinvasive Glaucoma Surgery
by: Chelvin C. A. Sng, et al.
Published: (2017-01-01) -
The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study
by: Xuenan Peng, et al.
Published: (2025-06-01) -
Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
by: Die Sang, et al.
Published: (2025-02-01) -
Safety and Efficacy of Microinvasive Glaucoma Surgery
by: David Z. Chen, et al.
Published: (2017-01-01)